Side effect of GilenyaSubscription
Progressive multifocal leukoencephalopathy has been added as an adverse event of unknown frequency to the summary of product characteristics for Gilenya (fingolimod; Novartis).
Side effects of ZytigaSubscription
Increased alanine aminotransferase and increased aspartate aminotransferase are now listed as common adverse reactions in the summary of product characteristics for Zytiga (abiraterone; Janssen-Cilag). Hepatitis fulminant and acute hepatic failure have been added as rare adverse reactions.
NICE does not recommend ibrutinibSubscription
The National Institute for Health and Care Excellence (NICE) has published draft guidance that does not recommend ibrutinib within its marketing authorisation for treating chronic lymphocytic leukaemia. A consultation on the guidance will be available on the NICE website until 23 March 2016.